81 research outputs found
Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory
Abstract Spondyloarthritides (SpA) include inflammatory joint diseases with various clinical phenotypes that may also include the axial skeleton and/or entheses. SpA include psoriatic arthritis, reactive arthritis, enteropathic arthritis and ankylosing spondylitis; the latter is frequently associated with extra-articular manifestations, such as uveitis, psoriasis, and inflammatory bowel disease. SpA are associated with the HLA-B27 allele and recognize T cells as key pathogenetic players. In contrast to other rheumatic diseases, SpA affect women and men equally and are not associated with detectable serum autoantibodies. In addition, but opposite to rheumatoid arthritis, SpA are responsive to treatment regimens including IL-23 or IL-17-targeting biologics, yet are virtually unresponsive to steroid treatment. Based on these differences with prototypical autoimmune diseases, such as rheumatoid arthritis or connective tissue diseases, SpA may be better classified among autoinflammatory diseases, with a predominant innate immunity involvement. This would rank SpA closer to gouty arthritis and periodic fevers in the spectrum of rheumatic diseases, as opposed to autoimmune-predominant diseases. We herein provide available literature on risk factors associated with SpA in support of this hypothesis with a specific focus on genetic and environmental factors
Clinical significance of rare serum autoantibodies in rheumatic diseases: a systematic literature review
The identification of serum autoantibodies is central in the diagnosis of systemic autoimmune rheumatic disease (SARD), and an increasing number of specificities have been detected in the past years. This allows an early diagnosis in the active phases of diseases, with the identification of specific disease subsets that may ultimately improve the disease outcomes. Thanks to the use of old and new laboratory techniques that are becoming increasingly available worldwide, the number of rheumatic patients with a specific autoantibody is increasing and this is improving also our knowledge of disease trigger mechanisms. The paradigmatic example is the plethora of serum autoantibodies described in polymyositis and dermatomyositis, coined myositis-specific antibodies (MSA) which include antibodies directed against tRNA synthetases, anti-SRP, anti-Mi-2, and anti-TIF-1Îł and can discriminate disease subtypes, particularly when associated with the risk of cancer. As a further example, anti-HMGCR antibodies have been reported in several studies in association with necrotizing autoimmune myositis that may follow statin use. To clarify the current knowledge on these rare specificities, we performed a systematic literature review. We focused on the main features associated to specific autoantibodies that are rarely identified in rheumatic disease, to increase the awareness and scientific knowledge on these autoantibodies in different ethnic groups worldwide.Fil: Ceribelli, Angela. Humanitas Research Hospital; Italia. UniversitĂ degli Studi di Milano; ItaliaFil: Isailovic, Natasa. Humanitas Research Hospital; ItaliaFil: De Santis, Maria. Humanitas Research Hospital; ItaliaFil: Generali, Elena. Humanitas Research Hospital; ItaliaFil: Gorlino, Carolina Virginia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - San Luis. Instituto Multidisciplinario de Investigaciones BiolĂłgicas de San Luis. Universidad Nacional de San Luis. Facultad de Ciencias FĂsico MatemĂĄticas y Naturales. Instituto Multidisciplinario de Investigaciones BiolĂłgicas de San Luis; Argentina. Humanitas Research Hospital; ItaliaFil: Palermo, Bianca. Humanitas Research Hospital; ItaliaFil: Selmi, Carlo. UniversitĂ degli Studi di Milano; Italia. Humanitas Research Hospital; Itali
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
Introduction
Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach.
Methods
Samples from 84 patients derived from two neoadjuvant AI therapy trials were subjected to copy number profiling by microarray-based comparative genomic hybridisation (aCGH, nâ=â84), gene expression profiling (nâ=â47), matched pre- and post-AI aCGH (nâ=â19 pairs) and Ki67-based AI-response analysis (nâ=â39).
Results
Integrative analysis of these datasets identified a set of nine genes that, when amplified, were associated with a poor response to AIs, and were significantly overexpressed when amplified, including CHKA, LRP5 and SAPS3. Functional validation in vitro, using cell lines with and without amplification of these genes (SUM44, MDA-MB134-VI, T47D and MCF7) and a model of acquired AI-resistance (MCF7-LTED) identified CHKA as a gene that when amplified modulates estrogen receptor (ER)-driven proliferation, ER/estrogen response element (ERE) transactivation, expression of ER-regulated genes and phosphorylation of V-AKT murine thymoma viral oncogene homolog 1 (AKT1).
Conclusions
These data provide a rationale for investigation of the role of CHKA in further models of de novo and acquired resistance to AIs, and provide proof of concept that integrative genomic analyses can identify biologically relevant modulators of AI response
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments
The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature
Introduction: Systemic sclerosis (SSc) is characterized by a complex etiopathogenesis encompassing both host genetic and environmental -infectious/toxic- factors responsible for altered fibrogenesis and diffuse microangiopathy. A wide spectrum of clinical phenotypes may be observed in patients' populations from different geographical areas. We investigated the prevalence of specific clinical and serological phenotypes in patients with definite SSc enrolled at tertiary referral centres in different Italian geographical macro-areas. The observed findings were compared with those reported in the world literature.Materials and methods: The clinical features of 1538 patients (161 M, 10.5%; mean age 59.8 +/- 26.9 yrs.; mean disease duration 8.9 +/- 7.7 yrs) with definite SSc recruited in 38 tertiary referral centres of the SPRING (Systemic sclerosis Progression INvestiGation Group) registry promoted by Italian Society of Rheumatology (SIR) were obtained and clustered according to Italian geographical macroareas.Results: Patients living in Southern Italy were characterized by more severe clinical and/or serological SSc phenotypes compared to those in Northern and Central Italy; namely, they show increased percentages of diffuse cutaneous SSc, digital ulcers, sicca syndrome, muscle involvement, arthritis, cardiopulmonary symptoms, interstitial lung involvement at HRCT, as well increased prevalence of serum anti-Scl70 autoantibodies. In the same SSc population immunusppressive drugs were frequently employed. The review of the literature underlined the geographical heterogeneity of SSc phenotypes, even if the observed findings are scarcely comparable due to the variability of methodological approaches.Conclusion: The phenotypical differences among SSc patients' subgroups from Italian macro-areas might be correlated to genetic/environmental co-factors, and possibly to a not equally distributed national network of information and healthcare facilities
Broad targeting of angiogenesis for cancer prevention and therapy
Deregulation of angiogenesis â the growth of new blood vessels from an existing vasculature â is a main driving force in many severe human diseases including cancer. As such, tumor angiogenesis is important for delivering oxygen and nutrients to growing tumors, and therefore considered an essential pathologic feature of cancer, while also playing a key role in enabling other aspects of tumor pathology such as metabolic deregulation and tumor dissemination/metastasis. Recently, inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development. Unfortunately the clinically approved anti-angiogenic drugs in use today are only effective in a subset of the patients, and many who initially respond develop resistance over time. Also, some of the anti-angiogenic drugs are toxic and it would be of great importance to identify alternative compounds, which could overcome these drawbacks and limitations of the currently available therapy. Finding âthe most important targetâ may, however, prove a very challenging approach as the tumor environment is highly diverse, consisting of many different cell types, all of which may contribute to tumor angiogenesis. Furthermore, the tumor cells themselves are genetically unstable, leading to a progressive increase in the number of different angiogenic factors produced as the cancer progresses to advanced stages. As an alternative approach to targeted therapy, options to broadly interfere with angiogenic signals by a mixture of non-toxic natural compound with pleiotropic actions were viewed by this team as an opportunity to develop a complementary anti-angiogenesis treatment option. As a part of the âHalifax Projectâ within the âGetting to know cancerâ framework, we have here, based on a thorough review of the literature, identified 10 important aspects of tumor angiogenesis and the pathological tumor vasculature which would be well suited as targets for anti-angiogenic therapy: (1) endothelial cell migration/tip cell formation, (2) structural abnormalities of tumor vessels, (3) hypoxia, (4) lymphangiogenesis, (5) elevated interstitial fluid pressure, (6) poor perfusion, (7) disrupted circadian rhythms, (8) tumor promoting inflammation, (9) tumor promoting fibroblasts and (10) tumor cell metabolism/acidosis. Following this analysis, we scrutinized the available literature on broadly acting anti-angiogenic natural products, with a focus on finding qualitative information on phytochemicals which could inhibit these targets and came up with 10 prototypical phytochemical compounds: (1) oleanolic acid, (2) tripterine, (3) silibinin, (4) curcumin, (5) epigallocatechin-gallate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) withaferin A and (10) resveratrol. We suggest that these plant-derived compounds could be combined to constitute a broader acting and more effective inhibitory cocktail at doses that would not be likely to cause excessive toxicity. All the targets and phytochemical approaches were further cross-validated against their effects on other essential tumorigenic pathways (based on the âhallmarksâ of cancer) in order to discover possible synergies or potentially harmful interactions, and were found to generally also have positive involvement in/effects on these other aspects of tumor biology. The aim is that this discussion could lead to the selection of combinations of such anti-angiogenic compounds which could be used in potent anti-tumor cocktails, for enhanced therapeutic efficacy, reduced toxicity and circumvention of single-agent anti-angiogenic resistance, as well as for possible use in primary or secondary cancer prevention strategies
Sex difference and intra-operative tidal volume: Insights from the LAS VEGAS study
BACKGROUND: One key element of lung-protective ventilation is the use of a low tidal volume (VT). A sex difference in use of low tidal volume ventilation (LTVV) has been described in critically ill ICU patients.OBJECTIVES: The aim of this study was to determine whether a sex difference in use of LTVV also exists in operating room patients, and if present what factors drive this difference.DESIGN, PATIENTS AND SETTING: This is a posthoc analysis of LAS VEGAS, a 1-week worldwide observational study in adults requiring intra-operative ventilation during general anaesthesia for surgery in 146 hospitals in 29 countries.MAIN OUTCOME MEASURES: Women and men were compared with respect to use of LTVV, defined as VT of 8âmlâkg-1 or less predicted bodyweight (PBW). A VT was deemed 'default' if the set VT was a round number. A mediation analysis assessed which factors may explain the sex difference in use of LTVV during intra-operative ventilation.RESULTS: This analysis includes 9864 patients, of whom 5425 (55%) were women. A default VT was often set, both in women and men; mode VT was 500âml. Median [IQR] VT was higher in women than in men (8.6 [7.7 to 9.6] vs. 7.6 [6.8 to 8.4] mlâkg-1 PBW, Pâ<â0.001). Compared with men, women were twice as likely not to receive LTVV [68.8 vs. 36.0%; relative risk ratio 2.1 (95% CI 1.9 to 2.1), Pâ<â0.001]. In the mediation analysis, patients' height and actual body weight (ABW) explained 81 and 18% of the sex difference in use of LTVV, respectively; it was not explained by the use of a default VT.CONCLUSION: In this worldwide cohort of patients receiving intra-operative ventilation during general anaesthesia for surgery, women received a higher VT than men during intra-operative ventilation. The risk for a female not to receive LTVV during surgery was double that of males. Height and ABW were the two mediators of the sex difference in use of LTVV.TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov, NCT01601223
Recommended from our members
Prevalence and Predictive Value of Disease Specific Autoantibodies over 13 Years in a Large Cohort Representative of the General Population of Northern Italy
Autoimmune diseases represent chronic disorders that affect a significant proportion of the population in Europe, with a impact on patientsâ quality of life and socioeconomic costs for the healthcare system and community. Virtually, all autoimmune diseases are associated with the presence of serum autoantibodies. After the preclinical period, clinical manifestations develop, and a delay in the diagnosis and treatment can account for further organ damage, physical and psychological disability that cause a reduction of the working capacity and finally a high economic impact on society. Based on these findings, we aimed to:
1. Estimate the prevalence of disease specific autoantibodies in the general population of an area of Lombardia region by using the most recently developed methods for the detection of autoantibodies.
2. Analyze the autoantibodies predictive value for the development of autoimmune diseases over 15 years of follow-up.
3. Analyze if there are factors at baseline that can predict the development of autoimmune disease over 15 years of follow-up, in order to identify patients at higher risk of developing an autoimmune disease that need a closer follow-up.
4. Analyze the autoantibodies predictive value for the development of malignancies over 15 years of follow-up.
Research design and methodology
The present study was conducted on two different cohorts derived from the general population of Lombardia region in Northern Italy: ISOLA (2,828 subjects) and CA.ME.LI.A. (CArdiovascular risk, MEtabolic syndrome, LIver, and Autoimmunity) (1,712 subjects). Serum samples were tested for serum autoantibodies (ANA, anti-ENA, rheumatoid factor, anti-CCP, anti-phospholipid antibodies, AMA, anti-LKM, anti-LC1, anti-SLA, anti-DGP, anti-tTG) using the most innovative techniques. Autoimmune diseases diagnosis were researched analyzing the administrative health databases. Furthermore, we detected hospitalization, cancer diagnosis, and death. In the CA.ME.LI.A. cohort cardiovascular risk factors were analyzed and 1/3 underwent carotid ultrasonographic analysis.
In summary, we report that:
1. Serum ANA are detected in up to 18% of the general population, being more frequent in women and in elder ages while being ANA associated with an higher risk of connective tissue disease development
2. Serum rheumatoid factor is detected in 8.1% of the general population, while serum anti-CCP are found in 4.8% of the population, the prevalence of double positivity is 0.6%.Anti-CCP are associated with a significant increased risk of RA development, while rheumatoid factor is associated with both HBV and HCV infection. Anti-CCP are associated with an increased risk of cancer and rheumatoid factor is associated with an increased risk of death..
3. Anti-phospholipid antibodies are detected in 15% of an unselected population, especially newly identified autoantibodies not currently included in the classification criteria. Anti-phospholipid antibodies are associated with an increased cardiovascular risk profile and independently with cardiovascular disease, especially subclinical atherosclerosis.
4. AMA are detected in 3.8%, but at high titer in 1% of an unselected population; we identified only two cases of PBC, of which only one was AMA positive therefore we cannot estimate the risk; anti-LKM, anti-SLA, anti-LC1 antibodies are rarely found.
5. Anti-DPG antibodies are detected in 1.85% of an unselected population, while, anti-tTG were found in 2.2%, with no differences between sexes. We identified 7 cases of coeliac disease, of which only one resulted positive for both anti-DPG and anti-tTG antibodies at high-titer.
In conclusion, autoantibodies are frequently found in subjects randomly selected from the general population, while being only seldom associated with an increased risk of developing an overt autoimmune disease. Furthermorre, autoantibodies may be associated with predisposing factors, as viral infections or cancer
Tumor Necrosis Factor-Alpha at the Crossroad between Rheumatoid Arthritis and Autoimmune Cholangitis
- âŠ